The herpes simplex virus 1 U L 3 and U L 4 open reading frames are expressed late in infection and are not essential for viral replication in cultured cells in vitro. An earlier report showed that the U L 4 protein colocalizes with the products of the ␣22/U S 1.5 genes in small nuclear dense bodies. Here we report that the U L 3 protein also colocalized in these small nuclear dense bodies and the localization of U L 3 and U L 4 proteins in these bodies required the presence of ␣22/U S 1.5 genes. In cells infected with a mutant lacking intact ␣22/U S 1.5 genes, U L 3 was diffused throughout the nucleus even though the overall accumulation of the ␥2 U L 3 protein was decreased. The results suggest that ICP22 acts both as a regulator of U L 3 accumulation and as the structural component and anchor of these small dense nuclear bodies.
Of the 84 open reading frames of herpes simplex virus 1 (HSV-1) known to be expressed in infected cells, more than half are dispensable for viral replication at least in some cell lines maintained in culture (18, 19) . These open reading frames appear to be essential for viral survival in nature, since viruses lacking these genes have not been isolated and in experimental animal systems mutants lacking these genes tend to be attenuated. In many instances the functions of these genes are difficult to study, since they appear to have no obvious phenotype in infected cells. This report is an extension of recently published studies on two such genes, U L 3 and U L 4 (8, 12) .
Both U L 3 and U L 4 are dispensable in all cell lines tested to date (3; N. S. Markovitz and B. Roizman, unpublished data). Neither gene appears to play a role in pathogenicity or latent infections caused by HSV-1 (9; J. D. Baines and B. Roizman, unpublished data). The U L 3 gene products are expressed as multiple isoforms: two isoforms result from alternate translation initiation of the U L 3 open reading frame; the phosphoisoforms result from posttranslational processing by U L 13 viral protein kinase and by at least one additional, as yet unidentified protein kinase (7, 12) . The HSV-2 U L 3 phosphoprotein is present in multiple isoforms and localizes in the nucleus after the onset of DNA synthesis (22) . Both U L 3 and U L 4 are late, or ␥2 proteins whose synthesis depends on the onset of viral DNA replication. HSV-1 and HSV-2 U L 4 proteins have been described elsewhere (5, 8, 23) . Recently this laboratory reported that U L 4 colocalizes with the products of the ␣22/U S 1.5 genes in the nucleus at 17 h after infection (8) .
The ␣22/U S 1.5 gene is located at the left terminus of the unique short sequence (U S ) when the genome is presented in its prototype orientation (4, 15, 21) . ␣22 encodes the 420-amino-acid ICP22. The U S 1.5 protein is expressed from a shorter mRNA and consists of approximately 60% of carboxylterminal amino acid sequence of the ICP22 (4). The shared portion of the ␣22/U S 1.5 gene products is required for efficient viral replication in rodent and rabbit cell lines (14) , and its presence enhances the expression of a subset of ␥2 genes (14, 16, 17, 20) . Although we refer to ICP22 in the colocalization studies, our studies do not differentiate between ICP22 and the U S 1.5 protein.
The studies described in this report utilized the F strain of HSV-1 [HSV-1(F)]. In the recombinant viruses R8105 and R4660, a sequence encoding an epitope reacting with an available monoclonal antibody was inserted in frame into the coding sequences of U L 3 and U L 4 genes, respectively (8, 12) . The monoclonal antibody CH28-2 (Goodwin Cancer Research Institute, Plantation, Fla.) reacts with an epitope mapped to the glycoprotein B of human cytomegalovirus and does not react with HSV-1 proteins (11). In recombinant virus R325, the carboxyl-terminal 220 amino acids of the ␣22/U S 1.5 gene had been deleted (15) . In the recombinant R4968, the deletion in ␣22 has been restored (13) . The origin and maintenance of the HEp-2 and rabbit skin cells have been described elsewhere (8, 12) . The antisera used in these studies have also been reported elsewhere. Briefly, rabbit antisera were raised against a chimeric protein containing amino acids 44 to 235 of the HSV-1 U L 3 protein and, separately, against the entire HSV-1 U L 4 protein (8, 12) . Rabbit antiserum (R77) to ICP22 was made against the amino-terminal domain of ICP22 and does not react with the U S 1.5 protein (2). The monoclonal antibody to ICP4 (H640) described elsewhere (1) was purchased from Goodwin Cancer Research Institute.
In the first of a series of immunofluorescence studies (data not shown), we noted that the pattern of U L 3 fluorescence was similar to that of small dense nuclear bodies containing both ICP22 and U L 4 (8) . Specifically, an earlier report showed that U L 4 protein colocalized with ICP22 in small dense nuclear structures (8) . To verify this conclusion, rabbit skin cells grown in wells on glass slides were exposed to approximately 10 PFU of HSV-1(F) or of recombinant virus per cell and incubated at 37°C. The cells were fixed at 17 h after infection in methanol and processed as described elsewhere (8) . The results were as follows.
(i) The U L 3 protein localized in small dense nuclear bodies ( Fig. 1A to C) . Furthermore, this experiment showed that identical images were obtained with antibody to the tag (fluorescein isothiocyanate [FITC] ) and the authentic antibody to the U L 3 protein (Texas red). Thus, as was the case for U L 4 (8), the virus carrying the tagged U L 3 could be used as a substitute for the untagged virus in double-label studies.
(ii) The U L 3 proteins colocalized with ICP22 in cells infected with R8105 (U L 3 epitope tagged) and reacted with the antibody against ICP22 (R77) and the anti-tag monoclonal antibody ( Fig. 1D to F) . In this instance the superimposition shown in Fig. 1F was not nearly as complete as that seen in Fig.  1C . It is noteworthy that in some of the dense bodies the U L 3 protein was either more diffuse or more abundant than ICP22.
(iii) The amount of U L 4 antigen was significantly lower than that of the U L 3 protein in cells infected with R8105 (U L 3 epitope tagged) and reacted with the rabbit polyclonal antibody to U L 4 and to the anti-tag monoclonal antibody. Nevertheless, the U L 3 and U L 4 proteins colocalized, especially in dense bodies in which the U L 4 protein was readily detectable (Fig. 1G to I ). The reverse experiment yielded results consistent with that conclusion. Specifically, in cells infected with R4660 (tagged U L 4) and reacted with the polyclonal rabbit antibody to U L 3 and the anti-tag monoclonal antibody, the signal for the tagged U L 4 protein was stronger than that obtained in Fig. 1G with the anti-U L 4 antibody. In this instance the two images produced by the two antibodies were superimposable.
(iv) We have selected rabbit skin cells for these studies on the basis of the observation that the nuclear structures containing U L 3 and U L 4 were larger or more readily detectable. Studies on infected HEp-2 cells yielded results identical to those described above (data not shown).
In earlier reports we described the properties of the antibodies to the U L 3, U L 4, and ICP22 proteins (2, 8, 12) . Relevant to the studies described here, the antibodies made against U L 3 and U L 4 are specific for each protein and do not crossreact. In both immunofluorescence and immunoblot assays, U L 3 and U L 4 proteins were not visualized when the anti-U L 4 and U L 3 antibodies, respectively, were used ( Fig. 2) (8, 12) , and U L 3 and U L 4 do not have protein sequence homology. We conclude from these studies that ICP22, U L 3, and U L 4 proteins colocalize in nuclear structures of infected cells.
The second series of experiments was prompted by earlier observations that ICP22 enhances the expression of a subset of ␥2 proteins and that modification of the phosphoprotein isoforms of U L 3 is mediated by the viral U L 13 protein kinase. In numerous studies, this laboratory has found a link between U L 13 protein kinase and ICP22 (14, 16, 17, 20) . In every case examined, the phenotype of U L 13
Ϫ mutants was similar to that of ␣22 Ϫ /U S 1.5 Ϫ mutants (13, 14, 16, 17) . To unravel the effect of ICP22 on the accumulation of U L 3 and U L 4, electrophoretically separated lysates of mock-infected cells or cells infected with HSV-1(F), R325 (⌬␣22/U S 1.5), or the repair virus R4968 were transferred to nitrocellulose sheets and probed with antibodies to either U L 3 or U L 4. The results of this experiment shown in Fig. 2 indicate that, consistent with earlier results (Markovitz and Roizman, unpublished), in cells infected with the R325 (⌬␣22/U S 1.5) virus, all isoforms of U L 3 protein were present but in smaller amounts than in cells infected with the wild-type virus or with the recombinant virus in which the ␣22 gene had been repaired (R4968) (Fig. 2, lanes 1 to 4) , whereas the levels of U L 4 protein showed a less dramatic decrease (Fig.  2, lanes 5 to 8) .
Since U L 4 and U L 3 proteins colocalize with ICP22 and deletion of ICP22 resulted in a decreased accumulation of U L 3 and, to a lesser extent, of U L 4 proteins, the question arose as to whether the localization of these proteins was affected in cells infected with the recombinant virus R325 from which the 8) . Lysates of cells mock infected or infected with HSV-1(F) or the indicated recombinant virus were prepared as described elsewhere (12) . FIG. 3 . Localization of U L 3 and U L 4 proteins and of ICP22 in infected cells. Rabbit skin cells were mock infected or exposed to 10 PFU of HSV-1(F) or R325 per cell and processed as described in the legend to Fig. 1 . Anti-mouse immunoglobulin conjugated to FITC (Sigma) was used to visualize the mouse monoclonal antibody to ICP4 (K). Ab., antibody.
carboxyl-terminal 220 codons of the ␣22 gene had been deleted. In this series of experiments, rabbit skin cells were mock infected or infected with HSV-1(F) or recombinant R325 virus and reacted with single antibodies (Fig. 3A to I ) or U L 4 and ICP4 antibodies (Fig. 3J and K) . The results were as follows.
(i) As expected, neither U L 3, U L 4, or ICP22 antibodies reacted with mock-infected cells (Fig. 3D to F) .
(ii) In HSV-1(F)-infected cells, polyclonal antibodies to U L 3, U L 4, and ICP22 reacted with their respective antigens in small dense nuclear structures (Fig. 3A to C) .
(iii) In R325 mutant-infected cells, the expression patterns of U L 3 and U L 4 differed from that observed in HSV-1(F)-infected cells in two respects. First, we observed that fewer infected rabbit skin cells expressed detectable U L 3 protein-a finding consistent with the observation that U L 3 protein accumulated in smaller amounts in cells infected with R325 recombinant virus than in cells infected with wild-type virus. The fraction of cells expressing U L 4 was also decreased in R325-infected cells. To verify that the difference in the proportion of cells expressing U L 3 and U L 4 in R325-infected cells was related to relative U L 3 and U L 4 levels and not to a difference in infectivity, replicate wells were reacted with antibodies to the ICP4 protein. Figure 3J and K show the same two cells. While virtually all cells were infected, as evidenced by the presence of the ICP4 protein (Fig. 3K) , only some cells were positive for U L 3 (data not shown) or U L 4 ( Fig. 3J) protein expression. Thus, the microscopic fields shown in Fig. 3J and K are identical; only one of the two infected cells shown in Fig. 3K contains U L 4 protein. The second interesting finding was that in the cells positive for U L 3 protein, the distribution of U L 3 was more diffuse, formed irregularly shaped structures that occupied a significantly larger portion of the nucleus (Fig. 3G  and H) . A similar phenomenon was observed for U L 4 (Fig. 3J) .
(iv) Studies on infected HEp-2 cells yielded results identical to those described above.
A curious phenomenon observed in these studies is that although U L 3 protein accumulated in reduced quantities in cells infected with ␣22 Ϫ /U S 1.5 Ϫ virus-infected cells, the quantity of U L 3 protein as measured by immunofluorescence appeared to be greater in those cells expressing U L 3 than that observed in cells infected with wild-type virus. One likely explanation is that in a dispersed mode, as seen in cells infected with ␣22 Ϫ /U S 1.5 Ϫ virus, the U L 3 protein was far more accessible to its antibody than in the compressed mode in the small, dense nuclear structures of cells infected with wild-type virus. We conclude from the studies described in this report the following.
(i) Both U L 3 and U L 4 are late or ␥2 genes dependent on viral DNA synthesis for their expression. Efficient accumulation of U L 3 protein, nascent or posttranslationally modified, requires the expression of U L 13 protein kinase (12) and of the ␣22/U S 1.5 genes. In the absence of the ␣22/U S 1.5 genes, neither U L 3 nor U L 4 localizes in the small dense nuclear structures seen in cells infected with wild-type virus. ICP22 by itself in transfection assays forms small dense nuclear bodies (V. Galvan and B. Roizman, unpublished data). Thus, no late protein is required for the formation of the dense bodies, since ICP22 alone is sufficient. Furthermore, the U L 3 and U L 4 genes do not have appreciable protein sequence homology. These results indicate that colocalization of U L 3 and U L 4 is directed by ICP22 rather than by the interaction of U L 3 and U L 4 proteins.
(ii) The function of these small dense nuclear bodies is not known. Earlier in infection, ICP22 localized in structures resembling the small dense nuclear structures described here. After the onset of viral DNA, ICP22 colocalizes with ICP4, RNA polymerase II, and nascent DNA and occupies a much larger volume than the small dense nuclear structures seen very early or very late in infection do (10) . Late in infection, ICP22 again localizes in small dense nuclear structures along with U L 3 and U L 4. The observation that ICP22 directs the localization of the newly synthesized U L 3 and U L 4 proteins to such structures suggests that they play a role in the viral replicative cycle late in infection.
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